• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Apixaban or rivaroxaban in the treatment of acute venous thromboembolism?

作者信息

Hellfritzsch Maja, Grove Erik L, Adelborg Kasper

机构信息

Clinical Pharmacology and Pharmacy, Department of Public Health, University of Southern Denmark, Odense, Denmark.

Department of Cardiology, Aarhus University Hospital, Aarhus, Denmark.

出版信息

Ann Transl Med. 2019 Sep;7(Suppl 6):S206. doi: 10.21037/atm.2019.07.03.

DOI:10.21037/atm.2019.07.03
PMID:31656785
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6789368/
Abstract
摘要

相似文献

1
Apixaban or rivaroxaban in the treatment of acute venous thromboembolism?阿哌沙班或利伐沙班用于治疗急性静脉血栓栓塞？
Ann Transl Med. 2019 Sep;7(Suppl 6):S206. doi: 10.21037/atm.2019.07.03.
2
Effectiveness and safety of apixaban versus rivaroxaban for prevention of recurrent venous thromboembolism and adverse bleeding events in patients with venous thromboembolism: a retrospective population-based cohort analysis.阿哌沙班与利伐沙班预防静脉血栓栓塞症患者复发性静脉血栓栓塞和不良出血事件的有效性及安全性：一项基于人群的回顾性队列分析。
Lancet Haematol. 2019 Jan;6(1):e20-e28. doi: 10.1016/S2352-3026(18)30191-1. Epub 2018 Dec 14.
3
Efficacy and safety of direct oral factor Xa inhibitors compared with warfarin in patients with morbid obesity: a single-centre, retrospective analysis of chart data.与华法林相比，直接口服Xa因子抑制剂在病态肥胖患者中的疗效和安全性：一项单中心图表数据回顾性分析
Lancet Haematol. 2019 Jul;6(7):e359-e365. doi: 10.1016/S2352-3026(19)30086-9. Epub 2019 May 24.
4
Comparison of apixaban to rivaroxaban and enoxaparin in acute cancer-associated venous thromboembolism.比较阿哌沙班、利伐沙班和依诺肝素在急性癌症相关性静脉血栓栓塞症中的应用。
Am J Hematol. 2019 Nov;94(11):1185-1192. doi: 10.1002/ajh.25604. Epub 2019 Aug 19.
5
Retrospective comparison of low molecular weight heparin vs. warfarin vs. oral Xa inhibitors for the prevention of recurrent venous thromboembolism in oncology patients: The Re-CLOT study.低分子量肝素与华法林及口服Xa因子抑制剂预防肿瘤患者复发性静脉血栓栓塞的回顾性比较：Re-CLOT研究
J Oncol Pharm Pract. 2018 Oct;24(7):494-500. doi: 10.1177/1078155217718382. Epub 2017 Jul 16.
6
Cost-effectiveness of rivaroxaban versus apixaban for the initial treatment of venous thromboembolism and extended prevention of recurrences in the UK.在英国，利伐沙班与阿哌沙班治疗静脉血栓栓塞初始治疗和延长复发预防的成本效益比较。
J Med Econ. 2019 Nov;22(11):1179-1191. doi: 10.1080/13696998.2019.1658589. Epub 2019 Sep 19.
7
Apixaban and Rivaroxaban in Patients With Acute Venous Thromboembolism.阿哌沙班和利伐沙班治疗急性静脉血栓栓塞症患者。
Mayo Clin Proc. 2019 Jul;94(7):1242-1252. doi: 10.1016/j.mayocp.2018.09.022. Epub 2019 Feb 6.
8
Temporal trends in initiation of VKA, rivaroxaban, apixaban and dabigatran for the treatment of venous thromboembolism - A Danish nationwide cohort study.华法林、利伐沙班、阿哌沙班和达比加群用于治疗静脉血栓栓塞症的起始时间趋势 - 一项丹麦全国性队列研究。
Sci Rep. 2017 Jun 13;7(1):3347. doi: 10.1038/s41598-017-03596-x.
9
Cost-effectiveness of Apixaban Versus Other Oral Anticoagulants for the Initial Treatment of Venous Thromboembolism and Prevention of Recurrence.阿哌沙班与其他口服抗凝剂用于静脉血栓栓塞初始治疗及预防复发的成本效益分析
Clin Ther. 2016 Mar;38(3):478-93.e1-16. doi: 10.1016/j.clinthera.2016.01.020. Epub 2016 Feb 26.
10
Safety and effectiveness of rivaroxaban and apixaban in patients with venous thromboembolism: a nationwide study.利伐沙班和阿哌沙班在静脉血栓栓塞患者中的安全性和有效性：一项全国性研究。
Eur Heart J Cardiovasc Pharmacother. 2018 Oct 1;4(4):220-227. doi: 10.1093/ehjcvp/pvy021.

引用本文的文献

1
Residual Vein Thrombosis After Deep Vein Thrombosis in Patients Treated with DOACs: Incidence and Associated Factors.接受直接口服抗凝剂治疗的患者深静脉血栓形成后的残余静脉血栓形成：发生率及相关因素
J Clin Med. 2025 Aug 25;14(17):5991. doi: 10.3390/jcm14175991.
2
Effectiveness and Safety of Nonvitamin K Oral Anticoagulants Rivaroxaban and Apixaban in Patients with Venous Thromboembolism: A Meta-Analysis of Real-World Studies.非维生素 K 口服抗凝剂利伐沙班和阿哌沙班治疗静脉血栓栓塞症患者的有效性和安全性：真实世界研究的荟萃分析。
Cardiovasc Ther. 2022 Jun 9;2022:2756682. doi: 10.1155/2022/2756682. eCollection 2022.

本文引用的文献

1
A changing landscape: Temporal trends in incidence and characteristics of patients hospitalized with venous thromboembolism 2006-2015.变化的格局：2006-2015 年静脉血栓栓塞症住院患者发病和特征的时间趋势。
Thromb Res. 2019 Apr;176:46-53. doi: 10.1016/j.thromres.2019.02.009. Epub 2019 Feb 13.
2
Effectiveness and safety of apixaban versus rivaroxaban for prevention of recurrent venous thromboembolism and adverse bleeding events in patients with venous thromboembolism: a retrospective population-based cohort analysis.阿哌沙班与利伐沙班预防静脉血栓栓塞症患者复发性静脉血栓栓塞和不良出血事件的有效性及安全性：一项基于人群的回顾性队列分析。
Lancet Haematol. 2019 Jan;6(1):e20-e28. doi: 10.1016/S2352-3026(18)30191-1. Epub 2018 Dec 14.
3
Prescription patterns of direct oral anticoagulants in pulmonary embolism: A prospective multicenter French registry.直接口服抗凝剂在肺栓塞中的处方模式：一项前瞻性多中心法国登记研究。
Thromb Res. 2019 Feb;174:27-33. doi: 10.1016/j.thromres.2018.12.013. Epub 2018 Dec 8.
4
Anticoagulant therapies for acute venous thromboembolism: a comparison between those discharged directly from the emergency department versus hospital in two Canadian cities.急性静脉血栓栓塞症的抗凝治疗：加拿大两个城市急诊科与医院直接出院患者的比较
BMJ Open. 2018 Oct 31;8(10):e022063. doi: 10.1136/bmjopen-2018-022063.
5
Safety and effectiveness of rivaroxaban and apixaban in patients with venous thromboembolism: a nationwide study.利伐沙班和阿哌沙班在静脉血栓栓塞患者中的安全性和有效性：一项全国性研究。
Eur Heart J Cardiovasc Pharmacother. 2018 Oct 1;4(4):220-227. doi: 10.1093/ehjcvp/pvy021.
6
Use of Non-Vitamin K Antagonist Oral Anticoagulants 2008-2016: A Danish Nationwide Cohort Study.2008-2016 年非维生素 K 拮抗剂口服抗凝剂的使用：一项丹麦全国队列研究。
Basic Clin Pharmacol Toxicol. 2018 Oct;123(4):452-463. doi: 10.1111/bcpt.13024. Epub 2018 Jun 5.
7
Real-World Use of Apixaban for Stroke Prevention in Atrial Fibrillation: A Systematic Review and Meta-Analysis.真实世界中阿哌沙班在房颤卒中预防中的应用：系统评价和荟萃分析。
Stroke. 2018 Jan;49(1):98-106. doi: 10.1161/STROKEAHA.117.018395. Epub 2017 Nov 22.
8
Prescription Patterns of Non-Vitamin K Oral Anticoagulants Across Indications and Factors Associated with Their Increased Prescribing in Atrial Fibrillation Between 2012-2015: A Study from the Norwegian Prescription Database.2012 - 2015年非维生素K口服抗凝剂在不同适应症中的处方模式以及与心房颤动中其处方增加相关的因素：来自挪威处方数据库的一项研究
Drugs Aging. 2017 Aug;34(8):635-645. doi: 10.1007/s40266-017-0476-4.
9
Temporal trends in initiation of VKA, rivaroxaban, apixaban and dabigatran for the treatment of venous thromboembolism - A Danish nationwide cohort study.华法林、利伐沙班、阿哌沙班和达比加群用于治疗静脉血栓栓塞症的起始时间趋势 - 一项丹麦全国性队列研究。
Sci Rep. 2017 Jun 13;7(1):3347. doi: 10.1038/s41598-017-03596-x.
10
Deep vein thrombosis and pulmonary embolism.深静脉血栓形成和肺栓塞。
Lancet. 2016 Dec 17;388(10063):3060-3073. doi: 10.1016/S0140-6736(16)30514-1. Epub 2016 Jun 30.